Brief: Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of Ide034, A Potential First-In-Class B7h3/Ptk7 Bispecific Top1 Adc
25/02/2026 11:06
Feb 25 (Reuters) - IDEAYA Biosciences Inc IDYA.O: IDEAYA BIOSCIENCES ANNOUNCES FIRST-PATIENT-IN FOR PHASE 1 TRIAL OF IDE034, A POTENTIAL FIRST-IN-CLASS B7H3/PTK7 BISPECIFIC TOP1 ADC IDEAYA BIOSCIENCES INC - FIRST PATIENT DOSING WITH IDE034 TRIGGERS $5 MILLION PAYMENT TO BIOCYTOGEN Source text: ID:nPnbfmTW4a Further company coverage: IDYA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on IDEAYA Biosciences
See all newsBrief: Ideaya Biosciences And Servier Announce Data From Three Clinical Trials At Esmo 2026 Supporting The Potential Of Darovasertib To Become A Foundational New Therapy For Patients Across The Treatment Journey Of Uveal Melanoma
Brief: Ideaya Biosciences Announces The Promotion Of Dr. Michael White To President, Research And Development
Brief: Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Ideaya Biosciences Inc Reports Results For The Quarter Ended June 30: Earnings Summary
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj